Tapentadol
drugOn this page
Also known as BN 200 (BASE)BN-200CG-5503CG5503CG5503 (BASE)CG5503 IRNSC-759619Tapentadol (hydrochloride)
Summary
Tapentadol (CHEMBL1201776) is an approved small molecule (ATC N02AX06) targeting OPRM1 and SLC6A2; indicated across 13 conditions including neoplasm and neuralgia.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: N02AX06
- Targets: 2 (OPRM1, SLC6A2)
- Indications: 13 conditions
- Clinical trials: 28
- Chemistry: 221.34 Da · C14H23NO
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201776 |
| Name | Tapentadol |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 9838022 |
| ATC | N02AX06 |
| Molecular formula | C14H23NO |
| Molecular weight | 221.34 |
| InChIKey | KWTWDQCKEHXFFR-SMDDNHRTSA-N |
SMILES: CC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C
IUPAC name: 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol
Also known as: BN 200 (BASE), BN-200, CG-5503, CG5503, CG5503 (BASE), CG5503 IR, NSC-759619, Tapentadol, TAPENTADOL, Tapentadol (hydrochloride)
Parent form; salt/anhydrous children: CHEMBL1201777
Patent coverage: 1,671 distinct patent families (6,081 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 6,064 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| OPRM1 | μ receptor | Agonist | 6.8 | 0% | P35372 |
| SLC6A2 | NET | Inhibition | 5.06 | 0.4% | P23975 |
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Mu-type opioid receptor, Solute carrier family 22 member 1.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| OPRM1 | 6.8 | Ki | 160 | nM | CHEMBL_ACT_10940221 |
| OPRM1 | 6.17 | EC50 | 670 | nM | CHEMBL_ACT_10940236 |
Target pathways
Aggregated over 2 target gene(s): OPRM1, SLC6A2.
Top Reactome pathways
14 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Opioid Signalling | 1 | OPRM1 |
| Disease | 1 | SLC6A2 |
| G-protein activation | 1 | OPRM1 |
| Peptide ligand-binding receptors | 1 | OPRM1 |
| Transport of small molecules | 1 | SLC6A2 |
| G alpha (i) signalling events | 1 | OPRM1 |
| R-HSA-425366 | 1 | SLC6A2 |
| SLC-mediated transmembrane transport | 1 | SLC6A2 |
| SLC-mediated transport of neurotransmitters | 1 | SLC6A2 |
| SLC transporter disorders | 1 | SLC6A2 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | 1 | SLC6A2 |
| Disorders of transmembrane transporters | 1 | SLC6A2 |
| Interleukin-4 and Interleukin-13 signaling | 1 | OPRM1 |
| MECP2 regulates neuronal receptors and channels | 1 | OPRM1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| G protein-coupled receptor signaling pathway | 1 |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 1 |
| adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway | 1 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 1 |
| neuropeptide signaling pathway | 1 |
| sensory perception | 1 |
| negative regulation of cell population proliferation | 1 |
| sensory perception of pain | 1 |
| G protein-coupled opioid receptor signaling pathway | 1 |
| negative regulation of nitric oxide biosynthetic process | 1 |
| behavioral response to ethanol | 1 |
| positive regulation of neurogenesis | 1 |
| negative regulation of cytosolic calcium ion concentration | 1 |
| negative regulation of Wnt protein secretion | 1 |
Indications & clinical
Indications
13 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 3 | MONDO:0005070 | EFO:0000616 |
| neuralgia | 3 | MONDO:0021667 | EFO:0005762 |
| diabetic neuropathy | 3 | MONDO:0006626 | EFO:1000783 |
| arthropathy | 3 | MONDO:0006816 | EFO:1000999 |
| osteoarthritis, knee | 3 | MONDO:0005416 | EFO:0004616 |
| osteoarthritis, hip | 3 | MONDO:0006629 | EFO:1000786 |
| osteoarthritis | 3 | MONDO:0005178 | MONDO:0005178 |
6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 28.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 13 |
| PHASE2 | 6 |
| PHASE4 | 4 |
| Not specified | 4 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06269770 | PHASE4 | RECRUITING | Tapentadol vs Tramadol in Total Knee Arthroplasty |
| NCT01458015 | PHASE4 | TERMINATED | Tapentadol Versus Oxycodone - a Mechanism-based Treatment Approach in Neuropathic Pain |
| NCT01500317 | PHASE4 | COMPLETED | Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans |
| NCT03314792 | PHASE4 | COMPLETED | Effects of Tapentadol Versus Oxycodone After Hysterectomy. |
| NCT00361504 | PHASE3 | COMPLETED | A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain |
| NCT00364247 | PHASE3 | COMPLETED | A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety. |
| NCT00421928 | PHASE3 | COMPLETED | Tapentadol (CG5503) |
| NCT00449176 | PHASE3 | COMPLETED | A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain |
| NCT00455520 | PHASE3 | COMPLETED | A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy |
| NCT00478023 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy |
| NCT00487435 | PHASE3 | COMPLETED | An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain |
| NCT00594516 | PHASE3 | COMPLETED | Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain |
| NCT00609466 | PHASE3 | COMPLETED | A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy |
| NCT00613938 | PHASE3 | COMPLETED | A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy. |
| NCT00983073 | PHASE3 | COMPLETED | Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Pain Due to Osteoarthritis Taking Either WHO Step I or Step II Analgesics or no Regular Analgesic |
| NCT02081391 | PHASE3 | COMPLETED | A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain |
| NCT02604446 | PHASE3 | COMPLETED | Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo |
| NCT01124617 | PHASE2 | COMPLETED | A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia |
| NCT01134536 | PHASE2 | COMPLETED | Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents |
| NCT01435577 | PHASE2 | COMPLETED | Intravenous Tapentadol in Post-Bunionectomy Pain |
| NCT01725087 | PHASE2 | COMPLETED | Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain. |
| NCT01729728 | PHASE2 | COMPLETED | Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain |
| NCT02221674 | PHASE2 | TERMINATED | Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old |
| NCT01877226 | PHASE1 | COMPLETED | Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants |
| NCT01946555 | Not specified | COMPLETED | Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain |
| NCT03351517 | Not specified | COMPLETED | Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty |
| NCT07320781 | Not specified | COMPLETED | Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients. |
| NCT07587645 | Not specified | COMPLETED | Tapentadol vs Pregabalin for Postoperative Pain in Lower Limb Surgery |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 17 clinical and 20 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
634 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| ALOGLIPTIN | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| AMITRIPTYLINE | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| Dihydroergotamine | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| GENTIAN VIOLET | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| IDELALISIB | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| PIMAVANSERIN | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| PROPOXYPHENE | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| REGORAFENIB | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| TAFENOQUINE | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| UMECLIDINIUM | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| VORAPAXAR | ChEMBL + PubChem | Phase 4 (approved) | OPRM1, SLC6A2 |
| AMBENONIUM | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| AMODIAQUINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| AMOXAPINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| ATOMOXETINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| AZELASTINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BENFLUOREX | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BENZIODARONE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BENZTROPINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BENZYDAMINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BEPRIDIL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BEXAROTENE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BITHIONOL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BOSUTINIB | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BROMODIPHENHYDRAMINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| BROMPERIDOL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CANDESARTAN CILEXETIL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CANNABIDIOL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CASPOFUNGIN | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CHLORHEXIDINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CHLORPROTHIXENE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CINACALCET | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CINNARIZINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CITALOPRAM | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CLEMASTINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CLOMIPHENE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CLOMIPRAMINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| COBIMETINIB | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| CYPROHEPTADINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DANAZOL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DEQUALINIUM | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DESOGESTREL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DESVENLAFAXINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DEXTROMETHORPHAN | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DIBENZEPIN | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DIETHYLSTILBESTROL | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DIPHENHYDRAMINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DIPHENYLPYRALINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DISULFIRAM | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DOBUTAMINE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
| DOMPERIDONE | ChEMBL | Phase 4 (approved) | OPRM1, SLC6A2 |
Related Atlas pages
- Genes: OPRM1, SLC6A2
- Diseases: neoplasm, neuralgia, diabetic neuropathy, arthropathy, osteoarthritis, knee, osteoarthritis, hip, osteoarthritis
- Drugs: Alogliptin, Amitriptyline, Dihydroergotamine, Idelalisib, Pimavanserin, Propoxyphene, Regorafenib, Tafenoquine, Umeclidinium, Vorapaxar, Ambenonium, Amiodarone, Amlodipine, Amodiaquine, Amoxapine, Aripiprazole, Astemizole, Atomoxetine, Azelastine, Bazedoxifene, Benfluorex, Benziodarone, Benztropine, Benzydamine, Bepridil, Bexarotene, Bithionol, Bosutinib, Bromodiphenhydramine, Bromperidol, Candesartan Cilexetil, Cannabidiol, Carvedilol, Caspofungin, Chlorhexidine, Chlorpromazine, Chlorprothixene, Cinacalcet, Cinnarizine, Citalopram, Clemastine, Clomiphene, Clomipramine, Clotrimazole, Cobimetinib, Cyproheptadine, Danazol, Daunorubicin, Dequalinium, Desogestrel, Desvenlafaxine, Dextromethorphan, Dibenzepin, Diethylstilbestrol, Diphenhydramine, Diphenylpyraline, Disulfiram, Dobutamine, Domperidone